Skip to main
INKT
INKT logo

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc. is experiencing promising early-stage results in its clinical trials, with improvements observed in pro-inflammatory markers, indicating potential responses in cancer treatment that could enhance the efficacy of their therapies. The company's CAR-iNKT therapies uniquely target solid tumors and demonstrate a favorable safety profile compared to traditional cell therapies, reinforcing the scientific rationale for their innovative approach to cancer treatment. Additionally, the decision to conduct an investigator-sponsored trial with external funding is strategically advantageous, allowing MiNK to explore new indications without straining its financial resources, thereby positioning the company for potential growth opportunities in both the short and long term.

Bears say

The negative outlook on MiNK Therapeutics's stock is primarily driven by substantial operational losses, notably a fourth-quarter 2024 operating loss of $2.5 million and an earnings per share (EPS) of -$0.62, indicating ongoing financial struggles. Additionally, the company faces significant risks, including potential safety issues arising from its clinical and preclinical programs and the possibility of lower than expected efficacy from these studies, which could hinder future growth and market acceptance. Furthermore, the need for approximately $55 million in additional financing through 2038, alongside cash runway concerns that extend only into mid-2025, raises questions about the company's financial sustainability and capacity to navigate competitive and regulatory challenges.

MiNK Therapeutics (INKT) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Buy based on their latest research and market trends.

According to 4 analysts, MiNK Therapeutics (INKT) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.